{"name":"Creabilis SA","slug":"creabilis-sa","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CT327 0.05%","genericName":"CT327 0.05%","slug":"ct327-0-05","indication":"Moderate to severe psoriasis","status":"phase_2"},{"name":"CT327 ointment","genericName":"CT327 ointment","slug":"ct327-ointment","indication":"Treatment of pain associated with psoriasis","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CT327 0.1%","genericName":"CT327 0.1%","slug":"ct327-0-1","indication":"Other","status":"phase_2"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"CT327 0.5%","genericName":"CT327 0.5%","slug":"ct327-0-5","indication":"Treatment of atopic dermatitis","status":"phase_2"}]}],"pipeline":[{"name":"CT327 0.05%","genericName":"CT327 0.05%","slug":"ct327-0-05","phase":"phase_2","mechanism":"CT327 is a selective inhibitor of 11β-HSD1.","indications":["Moderate to severe psoriasis"],"catalyst":""},{"name":"CT327 0.1%","genericName":"CT327 0.1%","slug":"ct327-0-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CT327 0.5%","genericName":"CT327 0.5%","slug":"ct327-0-5","phase":"phase_2","mechanism":"CT327 is a selective inhibitor of the 11β-HSD1 enzyme.","indications":["Treatment of atopic dermatitis"],"catalyst":""},{"name":"CT327 ointment","genericName":"CT327 ointment","slug":"ct327-ointment","phase":"phase_2","mechanism":"CT327 ointment is a topical treatment that targets the cannabinoid receptor type 2 (CB2) to reduce inflammation and pain.","indications":["Treatment of pain associated with psoriasis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPOG5wUjI5X3pxZUVnbEFHRkpRbWk5YTl6aTMyMXlUTkR4dzQtYUFjYWl2S2dtLVdncnFaVXlHX01QVDJaa05hRWFGbFhsTWhJdmVSX1J3REZSUEJ1YjJHQ2VvbnBzZExtUzhFT1RZclMzV1dSaF9fUndiS2RmdEstWGR0Mjl5dF9RWVljbktmVWpuVG9zeDRySUdMY2dDaUpLVjN0bURzRU1aejJyQjJQNXFQWFl4Q1BjekpId2p5QlM?oc=5","date":"2012-05-03","type":"pipeline","source":"Technology Networks","summary":"Creabilis Appoints Dr Simon Russell as Chief Business Officer - Technology Networks","headline":"Creabilis Appoints Dr Simon Russell as Chief Business Officer","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":4},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}